Developing a treatment to prevent allergic reactions to PEGylated medicines
Official title: IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody
Funded at Mucommune, LLC · NIH-11013882 · Data updated 2026-11-12
This study is looking at how to help people who have allergic reactions to certain medicines that contain PEG, by using a special form of PEG to stop those allergies and make the treatments work better and safer for them.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | January 22, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $291,458 |
| NIH project number | 5R43AI181354-02 |
| Project ID | NIH-11013882 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have experienced allergic reactions to PEGylated medications or have developed anti-PEG antibodies.
✕Less likely to help
Patients who do not use PEGylated medicines or have no history of allergic reactions to these treatments may not benefit from this research.
What this research studies
This research focuses on addressing the allergic responses that some patients experience when treated with PEGylated medicines, which are commonly used in various therapies. The approach involves using high molecular weight free polyethylene glycol (PEG) to saturate the antibodies that cause these allergic reactions, thereby restoring the effectiveness of the medications. By preventing the formation of anti-PEG antibodies, this intervention aims to improve patient safety and treatment outcomes for those affected by PEG allergies. The research includes both animal models and potential clinical applications to ensure the safety and efficacy of the proposed solution.
Why it matters
Potential benefit: If successful, this research could allow patients to safely receive PEGylated therapies without the risk of severe allergic reactions.
How similar studies have gone: Previous studies have shown promising results using similar approaches to mitigate allergic responses to PEGylated drugs, indicating potential for success in this research.
Where this research is happening
-
Mucommune, LLC
Morrisville, United States Active
Researchers
- Principal investigator: Kushiro, Keiichiro — Mucommune, LLC
- Study coordinator: Kushiro, Keiichiro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.